IFF sale signals ingredient suppliers are sharpening health-focused portfolios

IFF’s $4.3 billion sale of its Food Ingredients business is more than a clean-up of the portfolio. It is a clear move away from a broad, mixed ingredients model and toward the higher-margin health, nutrition and performance categories that now drive the sharpest growth in the sector.

The company said on May 29, 2026 that it agreed to sell the unit to funds advised by CVC Capital Partners at roughly 10x 2025 EBITDA. IFF will keep a 10% minority stake, which lets it stay exposed to future upside while trimming a business that generated nearly $3.1 billion in sales and about $430 million in EBITDA last year. IFF said the sale advances portfolio transformation, sharpens its focus on higher-growth, higher-margin businesses and strengthens the balance sheet.

That matters because the divested unit sat close to the center of modern protein reformulation. IFF’s Food Ingredients business supplied texturants, emulsifiers, plant-based solutions and specialty ingredients, including specialty soy and pea protein. Its 2025 annual report described the segment as covering natural, artificial and plant-based specialty food ingredients, plus value-added formulations, emulsifiers and sweeteners. In other words, this was not a side business. It was part of the machinery that helps brands make protein products behave better in the real world.

That is exactly where the market is heading. Alternative proteins still run into the same wall: taste, texture, mouthfeel and digestibility. ADM’s 2025 alternative protein outlook said improved taste and texture are increasingly important purchase drivers, and Cargill said 61% of consumers increased their protein intake in 2024, up from 48% in 2019. Put those numbers together and the message is hard to miss. Protein demand is rising, but buyers are not just asking for more grams on the label. They want better functionality, cleaner stories and fewer sensory trade-offs.

IFF’s move fits that shift. The company completed its merger with DuPont’s Nutrition & Biosciences business on February 1, 2021, building a wider platform around flavors, food protection, enzymes, probiotics and related solutions. By February 2026, it had already launched a sale process for Food Ingredients, signaling that the rethink was well under way before the CVC deal landed. The pattern is familiar across ingredients: big suppliers are carving off broad commodity exposure and concentrating on lanes where technical support, formulation work and health positioning can command better margins.

CVC’s backing suggests the business still has value as a standalone platform, especially with its long customer relationships and leadership in texturants, emulsifiers and plant-based systems. But the bigger signal is for the protein economy. Suppliers that can solve texture, taste, stability and label pressure in one package are becoming the ones worth chasing.